Finance Roundup: Tizona, Aspyrian Raise VC Cash; Two Biotechs Ready IPOs
This article was originally published in Scrip
Executive Summary
Immuno-oncology and targeted cancer therapies, especially when backed by seasoned drug development teams, continue to attract keen venture capital interest, as Tizona Therapeutics Inc. and Aspyrian Therapeutics Inc. demonstrated recently.
You may also be interested in...
Finance Watch: Rakuten Aspyrian Raises $150m VC Round For Laser-Activated Cancer Drugs
Private investors, including Japanese e-commerce mogul Hiroshi Mikitani, backed a $150m Series C round for Rakuten Aspyrian and its photoimmunotherapy platform. Also, pharma-backed therapeutic video game developer Akili boosts Series C to $68m, and Summit garners additional BARDA funding.
Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter
Venture capital investment in biopharmaceutical firms for the first half of 2017 show that this year is on track to exceed 2016 levels. Recent financings include two $50m Series C rounds for two different companies developing later-stage drugs for itching: Trevi and Menlo Therapeutics.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.